Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

GEORGE Z HAN

Allopathic & Osteopathic Physicians Dermatology

NPI
1912296963
CMS profile
1334558
Location
NEW YORK, NY

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2021 · Entire year

$155,912.42

162 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2021 · entire year · sorted by reported total

By paying entity

PY2021 · entire year · sorted by reported total

Page 3 of 4; records 101–150 of 162 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

GEORGE Z HAN

NPI 1912296963 · CMS profile ID 1334558

Allopathic & Osteopathic Physicians / Dermatology

NEW YORK, NY

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 4; records 101–150 of 162 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1912296963?year=2021&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
GEORGE Z HAN, NPI 1912296963, CMS profile ID 1334558. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 4; records 101–150 of 162 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1912296963?year=2021&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
APA 7
IndustryPayments. (2026). GEORGE Z HAN, NPI 1912296963, CMS profile ID 1334558. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 4; records 101–150 of 162 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1912296963?year=2021&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
Bluebook
GEORGE Z HAN, NPI 1912296963, CMS profile ID 1334558, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 4; records 101–150 of 162 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1912296963?year=2021&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30

162 matching records · $155,912.42 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 162 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–150 of 162.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
SUN PHARMACEUTICAL INDUSTRIES INC. $9,600.0005/20/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 851882647 CMS
AbbVie Inc. $14.3405/19/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794736083 CMS
Janssen Biotech, Inc. $38.4105/14/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788814883 CMS
SUN PHARMACEUTICAL INDUSTRIES INC. $1,600.0005/11/2021 Honoraria No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 851882617 CMS
SUN PHARMACEUTICAL INDUSTRIES INC. $34.4505/11/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 851882623 CMS
UCB, Inc. $10.8305/11/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 807351573 CMS
SUN PHARMACEUTICAL INDUSTRIES INC. $2,250.0005/07/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 851882641 CMS
AbbVie Inc. $23.1005/06/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794736079 CMS
AbbVie Inc. $2,875.0005/05/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794736077 CMS
LEO Pharma Inc. $26.3705/05/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 842200019 CMS
AbbVie Inc. $23.1504/30/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794736073 CMS
Ortho Dermatologics, a division of Bausch Health US, LLC $18.9904/29/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 849553061 CMS
Ortho Dermatologics, a division of Bausch Health US, LLC $1,400.0004/28/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 849553055 CMS
Novartis Pharmaceuticals Corporation $19.3704/27/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 812708843 CMS
PFIZER INC. $25.6204/27/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 833320885 CMS
VYNE Pharmaceuticals Inc. $22.4704/23/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 830828901 CMS
AbbVie Inc. $10.0804/20/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794736065 CMS
AbbVie Inc. $1.0004/20/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794736069 CMS
E.R. Squibb & Sons, L.L.C. $1,812.5004/19/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 783496003 CMS
Janssen Biotech, Inc. $26.1904/14/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788814885 CMS
UCB, Inc. $109.8704/14/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 807331835 CMS
AbbVie Inc. $16.9804/13/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794736061 CMS
UCB, Inc. $37.2204/10/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 807335367 CMS
GENZYME CORPORATION $2,464.0004/09/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 843667453 CMS
Ortho Dermatologics, a division of Bausch Health US, LLC $58.8004/07/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 849553065 CMS
Incyte Corporation $49.9103/30/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 835570309 CMS
AbbVie Inc. $575.0003/25/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794736057 CMS
AbbVie Inc. $1,725.0003/24/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794736053 CMS
AbbVie Inc. $67.5903/20/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794736049 CMS
SUN PHARMACEUTICAL INDUSTRIES INC. $1,600.0003/17/2021 Honoraria No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 851882611 CMS
SUN PHARMACEUTICAL INDUSTRIES INC. $34.4503/17/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 851882629 CMS
Janssen Biotech, Inc. $24.3603/16/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788814893 CMS
Regeneron Healthcare Solutions, Inc. $33.4803/13/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 809584461 CMS
Novartis Pharmaceuticals Corporation $12.7903/12/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 812708841 CMS
SUN PHARMACEUTICAL INDUSTRIES INC. $1,600.0003/11/2021 Honoraria No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 851882631 CMS
SUN PHARMACEUTICAL INDUSTRIES INC. $34.4503/11/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 851882635 CMS
Janssen Biotech, Inc. $35.1503/10/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788814891 CMS
Regeneron Healthcare Solutions, Inc. $1,760.0003/09/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 809584459 CMS
AbbVie Inc. $16.6903/03/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794736045 CMS
Janssen Biotech, Inc. $1,250.0003/02/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788814869 CMS
PFIZER INC. $27.7502/26/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 833311431 CMS
VYNE Pharmaceuticals Inc. $19.8302/26/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 830817001 CMS
SUN PHARMACEUTICAL INDUSTRIES INC. $103.0902/25/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 851882633 CMS
SUN PHARMACEUTICAL INDUSTRIES INC. $1,600.0002/25/2021 Honoraria No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 851882639 CMS
Lilly USA, LLC $2,800.0002/24/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 819077683 CMS
AbbVie Inc. $1,150.0002/19/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794736041 CMS
Regeneron Healthcare Solutions, Inc. $1,760.0002/18/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 809584457 CMS
SUN PHARMACEUTICAL INDUSTRIES INC. $1,600.0002/16/2021 Honoraria No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 851882605 CMS
SUN PHARMACEUTICAL INDUSTRIES INC. $34.4502/16/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 851882627 CMS
AbbVie Inc. $10.1702/11/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794736037 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $192,540.66 292
PY2020 $117,321.25 142
PY2021 $155,912.42 162
PY2022 $199,106.05 146
PY2023 $299,522.49 201
PY2024 $270,306.85 201
PY2025 $333,492.02 222

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $65,090.03 23
PY2024 Recipient $4,600.00 2
PY2024 Principal investigator $84,848.30 35
PY2023 Recipient $400.00 2
PY2023 Principal investigator $76,246.20 17
PY2022 Recipient $7,925.00 7
PY2022 Principal investigator $18,202.32 6
PY2021 Recipient $1,930.00 4
PY2021 Principal investigator $38,092.56 10
PY2020 Recipient $145.30 2
PY2020 Principal investigator $709,127.78 38
PY2019 Recipient $14,106.00 2
PY2019 Principal investigator $837,225.19 36

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

23 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $500.00 10/29/2025 Covered Recipient Teaching Hospital
KARMANOS CANCER HOSPITAL
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184130352
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $500.00 10/08/2025 Covered Recipient Teaching Hospital
KARMANOS CANCER HOSPITAL
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184130306
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,500.00 09/25/2025 Covered Recipient Teaching Hospital
KARMANOS CANCER HOSPITAL
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184130282
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,000.00 09/25/2025 Covered Recipient Teaching Hospital
KARMANOS CANCER HOSPITAL
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184130284
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $675.00 06/23/2025 Non-covered Recipient Entity
BIOMEDICAL RESEARCH ALLIANCE OF NEW YORK LLC
AN OPEN-LABEL SINGLE-ARM STUDY OF DUPILUMAB IN ADOLESCENT AND ADULT SKIN OF COLOR PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1184210246
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,500.00 06/23/2025 Non-covered Recipient Entity
BIOMEDICAL RESEARCH ALLIANCE OF NEW YORK LLC
AN OPEN-LABEL SINGLE-ARM STUDY OF DUPILUMAB IN ADOLESCENT AND ADULT SKIN OF COLOR PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1184210338
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,037.50 06/23/2025 Non-covered Recipient Entity
BIOMEDICAL RESEARCH ALLIANCE OF NEW YORK LLC
AN OPEN-LABEL SINGLE-ARM STUDY OF DUPILUMAB IN ADOLESCENT AND ADULT SKIN OF COLOR PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1184210356
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,687.50 03/12/2025 Non-covered Recipient Entity
BIOMEDICAL RESEARCH ALLIANCE OF NEW YORK LLC
AN OPEN-LABEL SINGLE-ARM STUDY OF DUPILUMAB IN ADOLESCENT AND ADULT SKIN OF COLOR PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1184171366
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,025.00 03/12/2025 Non-covered Recipient Entity
BIOMEDICAL RESEARCH ALLIANCE OF NEW YORK LLC
AN OPEN-LABEL SINGLE-ARM STUDY OF DUPILUMAB IN ADOLESCENT AND ADULT SKIN OF COLOR PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1184171368
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,500.00 03/12/2025 Non-covered Recipient Entity
BIOMEDICAL RESEARCH ALLIANCE OF NEW YORK LLC
AN OPEN-LABEL SINGLE-ARM STUDY OF DUPILUMAB IN ADOLESCENT AND ADULT SKIN OF COLOR PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1184171370
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,350.00 03/12/2025 Non-covered Recipient Entity
BIOMEDICAL RESEARCH ALLIANCE OF NEW YORK LLC
AN OPEN-LABEL SINGLE-ARM STUDY OF DUPILUMAB IN ADOLESCENT AND ADULT SKIN OF COLOR PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1184171372
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $20,000.00 03/06/2025 Covered Recipient Teaching Hospital
KARMANOS CANCER HOSPITAL
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184129768
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $6,000.00 03/06/2025 Covered Recipient Teaching Hospital
KARMANOS CANCER HOSPITAL
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184129770
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,500.00 03/06/2025 Covered Recipient Teaching Hospital
KARMANOS CANCER HOSPITAL
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184129772
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,500.00 03/06/2025 Covered Recipient Teaching Hospital
KARMANOS CANCER HOSPITAL
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184129774
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,500.00 03/06/2025 Covered Recipient Teaching Hospital
KARMANOS CANCER HOSPITAL
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184129776
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,040.00 03/06/2025 Covered Recipient Teaching Hospital
KARMANOS CANCER HOSPITAL
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184129778
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $75.01 02/27/2025 Non-covered Recipient Entity
BIOMEDICAL RESEARCH ALLIANCE OF NEW YORK LLC
AN OPEN-LABEL SINGLE-ARM STUDY OF DUPILUMAB IN ADOLESCENT AND ADULT SKIN OF COLOR PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1184155888
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $75.01 02/27/2025 Non-covered Recipient Entity
BIOMEDICAL RESEARCH ALLIANCE OF NEW YORK LLC
AN OPEN-LABEL SINGLE-ARM STUDY OF DUPILUMAB IN ADOLESCENT AND ADULT SKIN OF COLOR PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1184155890
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $75.01 02/27/2025 Non-covered Recipient Entity
BIOMEDICAL RESEARCH ALLIANCE OF NEW YORK LLC
AN OPEN-LABEL SINGLE-ARM STUDY OF DUPILUMAB IN ADOLESCENT AND ADULT SKIN OF COLOR PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1184155892
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,350.00 02/27/2025 Non-covered Recipient Entity
BIOMEDICAL RESEARCH ALLIANCE OF NEW YORK LLC
AN OPEN-LABEL SINGLE-ARM STUDY OF DUPILUMAB IN ADOLESCENT AND ADULT SKIN OF COLOR PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1184155894
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,350.00 02/27/2025 Non-covered Recipient Entity
BIOMEDICAL RESEARCH ALLIANCE OF NEW YORK LLC
AN OPEN-LABEL SINGLE-ARM STUDY OF DUPILUMAB IN ADOLESCENT AND ADULT SKIN OF COLOR PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1184155896
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,350.00 02/27/2025 Non-covered Recipient Entity
BIOMEDICAL RESEARCH ALLIANCE OF NEW YORK LLC
AN OPEN-LABEL SINGLE-ARM STUDY OF DUPILUMAB IN ADOLESCENT AND ADULT SKIN OF COLOR PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1184155914